Yarmolinsky J, Bull CJ, Vincent EE, et al. - This study was undertaken to assess the correlation of genetically proxied inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (ie, genetic variants related to lower function of HMG-CoA reductase, target of statins) with epithelial ovarian cancer among the general population and in BRCA1/2 mutation carriers. Researchers obtained summary statistics for these SNPs from a genome-wide association study (GWAS) meta-analysis of case-control analyses of invasive epithelial ovarian cancer in the Ovarian Cancer Association Consortium (OCAC; N = 63,347) and from a GWAS meta-analysis of retrospective cohort analyses of epithelial ovarian cancer among BRCA1/2 mutation carriers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA; N = 31,448). Individuals were included between 1973 and 2014 and followed up through 2015 across the 2 consortia. The results showed that genetically proxied inhibition of HMG-CoA reductase was significantly correlated with lower odds of epithelial ovarian cancer. Nevertheless, these data do not show risk reduction from medications that inhibit HMG-CoA reductase; the future study is required to evaluate whether there is a similar relationship with such medications.